Janssen’s prostate cancer treatment, apalutamide, has become the first drug to receive approval under a pilot work-sharing program for new chemical entities (NCEs) launched earlier this year by the ACSS Consortium, which brings together the regulatory agencies of Australia, Canada, Singapore and Switzerland.
The product has been authorized for marketing in two of the participating countries, Australia and Canada, where it will be...






